Literature DB >> 8730644

Is aspirin, as used for antithrombosis, an emotion-modulating agent?

M W Ketterer1, J Brymer, K Rhoads, P Kraft, W R Lovallo.   

Abstract

Antiplatelet substances, generally aspirin, have become widely used for secondary prevention of ischemic heart disease. Used in relatively small doses, it is generally assumed that aspirin has no psychoactive effect. The present study took advantage of a sample of 174 males undergoing coronary angiography to see if regular aspirin use as prophylactic therapy for ischemic heart disease was associated with one or more of a number of measures of emotional distress. Aspirin use was found to be associated with less depression and anxiety or worry, as reported by the patient and as perceived by a significant other. Despite a significant association of aspirin use with the presence of documented coronary artery disease, the association of aspirin use and diminished distress could not be accounted for by the previously observed high prevalence of depressed/anxious individuals among patients with negative or nominal results on angiography, or by a number of other demographic or clinical variables such as age and socioeconomic status. Although only correlational in nature, present results raise the question of whether aspirin may have a beneficial mood-modulating effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8730644     DOI: 10.1016/0022-3999(95)00524-2

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  12 in total

1.  Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites.

Authors:  Mireille Basselin; Epolia Ramadan; Mei Chen; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

2.  Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism.

Authors:  Sandra Ghelardoni; Richard P Bazinet; Stanley I Rapoport; Francesca Bosetti
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

Review 3.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.

Authors:  Stanley I Rapoport
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

Review 5.  Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?

Authors:  Karen Wager-Smith; Athina Markou
Journal:  Neurosci Biobehav Rev       Date:  2010-09-29       Impact factor: 8.989

6.  Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.

Authors:  Pieter Stolk; Patrick C Souverein; Ingeborg Wilting; Hubert G M Leufkens; Donald F Klein; Stanley I Rapoport; Eibert R Heerdink
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-11-25       Impact factor: 4.006

Review 7.  Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.

Authors:  Tatsurou Yagami; Hiromi Koma; Yasuhiro Yamamoto
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

Review 8.  Bipolar disorder and mechanisms of action of mood stabilizers.

Authors:  Stanley I Rapoport; Mireille Basselin; Hyung-Wook Kim; Jagadeesh S Rao
Journal:  Brain Res Rev       Date:  2009-06-23

9.  Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.

Authors:  Jonathan Savitz; Sheldon Preskorn; T Kent Teague; Douglas Drevets; William Yates; Wayne Drevets
Journal:  BMJ Open       Date:  2012-02-22       Impact factor: 2.692

10.  Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression?

Authors:  Juan Gibert Rahola
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.